- 发布日期： 2023-02-21
- 更新日期： 2023-03-29
Darbufelone is a non-competitive dual inhibitor of PGF2α and LTB4. Dabfilon effectively inhibits PGHS-2 with a Ki of 10 μM and IC50s of 0.19 μM and 20 μM for PGHS-2 and PGHS-1.
Darbufelone (5 - 60 μM) increases the cell growth inhibitory effects in A549, H520 and H460 cell lines with IC50s of 20, 21 and 15 μM.
Darbufelone (80 mg/kg/day) decreases the tumor volumes in a time-dependent manner. Darbufelone (20 or 40 mg/kg/day) dos not show any significant inhibition of tumor weight. At necropsy, Darbufelone (80 mg/kg/day) reduces the tumor weight by 30.2%.
Johnson AR, et al. Slow-binding inhibition of human prostaglandin endoperoxide synthase-2 with darbufelone, an isoform-selective antiinflammatory di-tert-butyl phenol. Biochemistry. 2001 Jun 26;40(25):7736-45.
Ye X, et al. Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo. Cancer Chemother Pharmacol. 2010 Jul;66(2):277-85.
( < 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
For research use only .